YOLO (You Only Look Once) is an extensively utilized object detection algorithm that has found applications in various medical object detection tasks. This has been accompanied by the emergence of numerous novel variants in recent years, such as YOLOv7 and YOLOv8. This study encompasses a systematic exploration of the PubMed database to identify peer-reviewed articles published between 2018 and 2023. The search procedure found 124 relevant studies that employed YOLO for diverse tasks including lesion detection, skin lesion classification, retinal abnormality identification, cardiac abnormality detection, brain tumor segmentation, and personal protective equipment detection. The findings demonstrated the effectiveness of YOLO in outperforming alternative existing methods for these tasks. However, the review also unveiled certain limitations, such as well-balanced and annotated datasets, and the high computational demands. To conclude, the review highlights the identified research gaps and proposes future directions for leveraging the potential of YOLO for medical object detection.

The COVID-19 pandemic has emphasized the need for novel drug discovery process. However, the journey from conceptualizing a drug to its eventual implementation in clinical settings is a long, complex, and expensive process, with many potential points of failure. Over the past decade, a vast growth in medical information has coincided with advances in computational hardware (cloud computing, GPUs, and TPUs) and the rise of deep learning. Medical data generated from large molecular screening profiles, personal health or pathology records, and public health organizations could benefit from analysis by Artificial Intelligence (AI) approaches to speed up and prevent failures in the drug discovery pipeline. We present applications of AI at various stages of drug discovery pipelines, including the inherently computational approaches of de novo design and prediction of a drug's likely properties. Open-source databases and AI-based software tools that facilitate drug design are discussed along with their associated problems of molecule representation, data collection, complexity, labeling, and disparities among labels. How contemporary AI methods, such as graph neural networks, reinforcement learning, and generated models, along with structure-based methods, (i.e., molecular dynamics simulations and molecular docking) can contribute to drug discovery applications and analysis of drug responses is also explored. Finally, recent developments and investments in AI-based start-up companies for biotechnology, drug design and their current progress, hopes and promotions are discussed in this article.

Data generated from sources such as wearable sensors, medical imaging, personal health records, pathology records, and public health organizations have resulted in a massive information increase in the medical sciences over the last decade. Advances in computational hardware, such as cloud computing, Graphical Processing Units (GPUs), and Tensor Processing Units (TPUs), provide the means to utilize these data. Consequently, many Artificial Intelligence (AI)-based methods have been developed to infer from large healthcare data. Here, we present an overview of recent progress in artificial intelligence and biosensors in medical and life sciences. We discuss the role of machine learning in medical imaging, precision medicine, and biosensors for the Internet of Things (IoT). We review the most recent advancements in wearable biosensing technologies that use AI to assist in monitoring bodily electro-physiological and electro-chemical signals and disease diagnosis, demonstrating the trend towards personalized medicine with highly effective, inexpensive, and precise point-of-care treatment. Furthermore, an overview of the advances in computing technologies, such as accelerated artificial intelligence, edge computing, and federated learning for medical data, are also documented. Finally, we investigate challenges in data-driven AI approaches, the potential issues that biosensors and IoT-based healthcare generate, and the distribution shifts that occur among different data modalities, concluding with an overview of future prospects.

The identification of biomarkers plays a crucial role in personalized medicine, both in the clinical and research settings. However, the contrast between predictive and prognostic biomarkers can be challenging due to the overlap between the two. A prognostic biomarker predicts the future outcome of cancer, regardless of treatment, and a predictive biomarker predicts the effectiveness of a therapeutic intervention. Misclassifying a prognostic biomarker as predictive (or vice versa) can have serious financial and personal consequences for patients. To address this issue, various statistical and machine learning approaches have been developed. The aim of this study is to present an in-depth analysis of recent advancements, trends, challenges, and future prospects in biomarker identification. A systematic search was conducted using PubMed to identify relevant studies published between 2017 and 2023. The selected studies were analyzed to better understand the concept of biomarker identification, evaluate machine learning methods, assess the level of research activity, and highlight the application of these methods in cancer research and treatment. Furthermore, existing obstacles and concerns are discussed to identify prospective research areas. We believe that this review will serve as a valuable resource for researchers, providing insights into the methods and approaches used in biomarker discovery and identifying future research opportunities.